Louisiana State Employees Retirement System Takes Position in Revvity Inc. $RVTY

Louisiana State Employees Retirement System purchased a new position in shares of Revvity Inc. (NYSE:RVTY) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,800 shares of the company’s stock, valued at approximately $508,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Contravisory Investment Management Inc. acquired a new stake in shares of Revvity during the 1st quarter valued at $66,000. Assenagon Asset Management S.A. acquired a new position in shares of Revvity in the first quarter worth $2,105,000. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of Revvity during the first quarter worth $40,411,000. Corient Private Wealth LLC raised its holdings in shares of Revvity by 985.0% during the fourth quarter. Corient Private Wealth LLC now owns 126,568 shares of the company’s stock worth $12,245,000 after acquiring an additional 114,903 shares in the last quarter. Finally, SHP Wealth Management acquired a new stake in Revvity during the fourth quarter valued at $100,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Barclays upped their target price on Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Evercore restated an “outperform” rating and issued a $125.00 price objective on shares of Revvity in a report on Monday. Stifel Nicolaus reduced their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th. Finally, Robert W. Baird set a $117.00 target price on shares of Revvity in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $108.92.

Revvity Price Performance

NYSE RVTY opened at $112.15 on Wednesday. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $118.30. The company has a fifty day simple moving average of $100.42 and a 200 day simple moving average of $98.36. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The company has a market cap of $12.51 billion, a P/E ratio of 53.66, a P/E/G ratio of 2.47 and a beta of 1.09.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $711.12 million during the quarter, compared to analyst estimates of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 EPS. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, sell-side analysts predict that Revvity Inc. will post 5.25 EPS for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 17th. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio is presently 13.40%.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.